Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2020-10-01 Regulatory Filings
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Enlivex Therapeutics Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It announces the issuance of a press release about positive top-line clinical trial results. The document is short (2007 characters) and primarily serves to furnish a press release as an exhibit. There is no detailed financial data, comprehensive report, or management discussion included. This fits the profile of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for filings that do not fit other specific categories.
2020-10-01 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release about a patent allowance notice and is relatively short (2118 characters). It does not contain detailed financial statements or substantive financial data. The document primarily serves as a regulatory announcement rather than a full report like an annual or interim report. According to the rules, Form 6-K filings are typically classified under Regulatory Filings (RNS) as they are miscellaneous regulatory announcements that do not fit other specific categories.
2020-09-16 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release about a patent allowance notice. The document length is 2091 characters, which is relatively short and mainly serves as an announcement rather than a full report. It does not contain detailed financial statements or substantive financial data. The content is primarily a regulatory filing to inform the market of a material event. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a full report or other specific filing types.
2020-08-25 English
REPORT OF FOREIGN PRIVATE ISSUER
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Enlivex Therapeutics Ltd., with the SEC. It contains unaudited condensed consolidated financial statements and an Operating and Financial Review and Prospects for the three and six-month periods ended June 30, 2020 and 2019. Form 6-K is used for interim or quarterly reports by foreign private issuers. The document includes substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. The document length is 2556 characters, which is sufficient to contain actual financial data, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2020-08-14 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release about dosing the first patient in a clinical trial, but does not contain comprehensive financial statements or detailed financial analysis. The document length is 2166 characters, which is relatively short and primarily serves as an announcement rather than a full report. It references a press release as an exhibit, indicating it is providing regulatory disclosure rather than a full financial or management report. Form 6-K filings are typically classified under Regulatory Filings (RNS) as they are miscellaneous regulatory disclosures by foreign issuers that do not fit into other specific categories like Annual Reports or Earnings Releases.
2020-08-10 English
REPORT OF FOREIGN PRIVATE ISSUER
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Enlivex Therapeutics Ltd., reporting on the results of its 2020 Annual and Extraordinary General Meeting of Shareholders. It details shareholder voting results on board re-elections, amendments to agreements, compensation policies, indemnification agreements, and auditor reappointment. The document also mentions that the Annual Report and financial statements for the year ended December 31, 2019 were discussed at the meeting, but does not contain the report itself. The document is relatively short (3947 characters) and serves as an announcement of voting results and meeting outcomes rather than the full report or financial statements. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-06-29 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.